It has been shown that VM structures are dependent on CXCR2 expression in GBM patients [50,60], therefore, Angara et al. chose to combine AAT with an CXCR2 antagonist to prevent the development of VM [50]. The gene discussed is CXCR2; the disease is glioblastoma.